Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Dual SMO/BRAF Inhibition by Flavonolignans from Silybum marianum†

A. Diukendjieva, MM. Zaharieva, M. Mori, P. Alov, I. Tsakovska, T. Pencheva, H. Najdenski, V. Křen, C. Felici, F. Bufalieri, L. Di Marcotullio, B. Botta, M. Botta, I. Pajeva,

. 2020 ; 9 (5) : . [pub] 20200505

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20019230

Grantová podpora
DCM#577/17.08.2018 Bulgarian Ministry of Education and Science, National Research Program "Healthy Foods for a Strong Bio-Economy and Quality of Life"
STSM grant to Antonia Diukendjieva COST Action CM 1407 "Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery"
#IG20801 to Lucia Di Marcotullio Associazione Italiana Ricerca Cancro (AIRC)
18-00150S to Vladimir Kren Czech Science Foundation

Silymarin is the standardized extract from the fruits of Silybum marianum (L.) Gaertn., a well-known hepatoprotectant and antioxidant. Recently, bioactive compounds of silymarin, i.e., silybins and their 2,3-dehydro derivatives, have been shown to exert anticancer activities, yet with unclear mechanisms. This study combines in silico and in vitro methods to reveal the potential interactions of optically pure silybins and dehydrosilybins with novel protein targets. The shape and chemical similarity with approved drugs were evaluated in silico, and the potential for interaction with the Hedgehog pathway receptor Smoothened (SMO) and BRAF kinase was confirmed by molecular docking. In vitro studies on SMO and BRAF V600E kinase activity and in BRAF V600E A-375 human melanoma cell lines were further performed to examine their effects on these proteins and cancer cell lines and to corroborate computational predictions. Our in silico results direct to new potential targets of silymarin constituents as dual inhibitors of BRAF and SMO, two major targets in anticancer therapy. The experimental studies confirm that BRAF kinase and SMO may be involved in mechanisms of anticancer activities, demonstrating dose-dependent profiles, with dehydrosilybins showing stronger effects than silybins. The results of this work outline the dual SMO/BRAF effect of flavonolignans from Silybum marianum with potential clinical significance. Our approach can be applied to other natural products to reveal their potential targets and mechanism of action.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20019230
003      
CZ-PrNML
005      
20201123123830.0
007      
ta
008      
201103s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/antiox9050384 $2 doi
035    __
$a (PubMed)32380762
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Diukendjieva, Antonia $u Department of QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
245    10
$a Dual SMO/BRAF Inhibition by Flavonolignans from Silybum marianum† / $c A. Diukendjieva, MM. Zaharieva, M. Mori, P. Alov, I. Tsakovska, T. Pencheva, H. Najdenski, V. Křen, C. Felici, F. Bufalieri, L. Di Marcotullio, B. Botta, M. Botta, I. Pajeva,
520    9_
$a Silymarin is the standardized extract from the fruits of Silybum marianum (L.) Gaertn., a well-known hepatoprotectant and antioxidant. Recently, bioactive compounds of silymarin, i.e., silybins and their 2,3-dehydro derivatives, have been shown to exert anticancer activities, yet with unclear mechanisms. This study combines in silico and in vitro methods to reveal the potential interactions of optically pure silybins and dehydrosilybins with novel protein targets. The shape and chemical similarity with approved drugs were evaluated in silico, and the potential for interaction with the Hedgehog pathway receptor Smoothened (SMO) and BRAF kinase was confirmed by molecular docking. In vitro studies on SMO and BRAF V600E kinase activity and in BRAF V600E A-375 human melanoma cell lines were further performed to examine their effects on these proteins and cancer cell lines and to corroborate computational predictions. Our in silico results direct to new potential targets of silymarin constituents as dual inhibitors of BRAF and SMO, two major targets in anticancer therapy. The experimental studies confirm that BRAF kinase and SMO may be involved in mechanisms of anticancer activities, demonstrating dose-dependent profiles, with dehydrosilybins showing stronger effects than silybins. The results of this work outline the dual SMO/BRAF effect of flavonolignans from Silybum marianum with potential clinical significance. Our approach can be applied to other natural products to reveal their potential targets and mechanism of action.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zaharieva, Maya M $u Department of Infectious Microbiology, Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
700    1_
$a Mori, Mattia $u Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, 53100 Siena, Italy.
700    1_
$a Alov, Petko $u Department of QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
700    1_
$a Tsakovska, Ivanka $u Department of QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
700    1_
$a Pencheva, Tania $u Department of QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
700    1_
$a Najdenski, Hristo $u Department of Infectious Microbiology, Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
700    1_
$a Křen, Vladimír $u Laboratory of Biotransformation, Institute of Microbiology of the Czech Academy of Sciences, 14220 Prague, Czech Republic.
700    1_
$a Felici, Chiara $u Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
700    1_
$a Bufalieri, Francesca $u Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
700    1_
$a Di Marcotullio, Lucia $u Department of Molecular Medicine, Laboratory Affiliated to Istituto Pasteur Italia Fondazione Cenci Bolognetti, Sapienza University of Rome, 00185 Rome, Italy.
700    1_
$a Botta, Bruno $u Department of Chemistry and Technology of Drugs, Sapienza University of Rome, 00185 Rome, Italy.
700    1_
$a Botta, Maurizio $u Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, 53100 Siena, Italy.
700    1_
$a Pajeva, Ilza $u Department of QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
773    0_
$w MED00200130 $t Antioxidants (Basel, Switzerland) $x 2076-3921 $g Roč. 9, č. 5 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32380762 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201103 $b ABA008
991    __
$a 20201123123829 $b ABA008
999    __
$a ind $b bmc $g 1586010 $s 1109428
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 9 $c 5 $e 20200505 $i 2076-3921 $m Antioxidants $n Antioxidants $x MED00200130
GRA    __
$a DCM#577/17.08.2018 $p Bulgarian Ministry of Education and Science, National Research Program "Healthy Foods for a Strong Bio-Economy and Quality of Life"
GRA    __
$a STSM grant to Antonia Diukendjieva $p COST Action CM 1407 "Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery"
GRA    __
$a #IG20801 to Lucia Di Marcotullio $p Associazione Italiana Ricerca Cancro (AIRC)
GRA    __
$a 18-00150S to Vladimir Kren $p Czech Science Foundation
LZP    __
$a Pubmed-20201103

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...